John W Ryder
Affiliation: Eli Lilly and Company
- Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptorsJohn W Ryder
Neuroscience Division, Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 46285, USA
J Pharmacol Exp Ther 319:293-8. 2006..Taken together, these data indicate that the cGMP system may play an important role in pharmacological efficacy of the biarylpropylsulfonamide class of AMPA receptor potentiators...
- Divergent roles of GSK3 and CDK5 in APP processingJohn Ryder
Neuroscience Discovery Research, Lilly Research Laboratories, Indianapolis, IN 46285, USA
Biochem Biophys Res Commun 312:922-9. 2003..Our data support a function for both GSK3 and CDK5 in APP processing, further implicating these two kinases in the pathogenesis of Alzheimer's disease...
- Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting RhoYan Zhou
Neuroscience Discovery Research and Bioresearch Technologies and Proteins, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
Science 302:1215-7. 2003..Thus, the Rho-Rock pathway may regulate amyloid precursor protein processing, and a subset of NSAIDs can reduce Abeta42 through inhibition of Rho activity...
- Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areasKenneth W Perry
Neuroscience Discovery Research, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
Neuropharmacology 55:743-54. 2008..High levels of glycine in these brain areas may result in activation of strychnine-sensitive glycine A receptors that are inhibitory on both motor activity and critical brain stem functions such as respiration...